Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2015 | Advances in the treatment of CLL at ASCO 2015

Stephan Stilgenbauer • 2 Jun 2015
ASCO 2015
Chronic Lymphocytic Leukemia

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing chronic lymphocytic leukemia (CLL) treatment landscape. With the development of many new agents, researchers are now investigating how these agents can be optimized in the clinic.

More from Stephan Stilgenbauer

2:00
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Stephan Stilgenbauer • 11 Dec 2023
2:52
Acquired mutations associated with resistance to BTKi in patients with CLL
Stephan Stilgenbauer • 11 Dec 2023
2:51
Genetic markers in patients with early-stage CLL treated with ibrutinib: findings from CLL12
Stephan Stilgenbauer • 11 Dec 2023
2:11
Pre-clinical study on the dual BCL2/BCL-XL inhibitor AZD0466 for the treatment of CLL
Stephan Stilgenbauer • 11 Dec 2023

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals